Instrument Inactif

Communiqués Tenax Therapeutics Inc Nasdaq

Actions

US88032L1008

Recherche biotechnologique et médicale

Communiqués

13:09	Tenax Therapeutics: Q2 Earnings Snapshot	AQ
13:01	Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	AQ
02/07	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
02/07	Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026	AQ
12/05	Tenax Therapeutics: Q1 Earnings Snapshot	AQ
12/05	Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	AQ
08/05	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
04/05	Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer	AQ
22/04	Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer	AQ
10/03	Tenax Therapeutics: Q4 Earnings Snapshot	AQ
10/03	Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update	AQ
03/03	Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference	AQ
04/02	Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026	AQ
18/12	Tenax Therapeutics : Announces Result of Prespecified Blinded Sample Size Assessment	PU
17/12	Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment	AQ
25/11	Tenax Therapeutics to Participate in Upcoming Investor Conferences	AQ
14/11	Tenax Therapeutics : Virtual KOL Call (cde979)	PU
12/11	Tenax Therapeutics: Q3 Earnings Snapshot	AQ
12/11	Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update	AQ
06/11	Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF	AQ
03/11	Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference	AQ
16/09/25	Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF	AQ
28/08/25	Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025	AQ
13/08/25	Tenax Therapeutics: Q2 Earnings Snapshot	AQ
13/08/25	Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update	AQ